You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameSCH-530348
Accession NumberDB05692
TypeSmall Molecule
GroupsInvestigational
DescriptionSCH 530348 is new oral antiplatelet drug under development by Schering-Plough for the treatment and prevention of atherothrombotic events in patients with Acute Coronary Syndrome (ACS), previous Myocardial Infarction (MI), stroke, or existing peripheral arterial disease. On the back of successful phase II clinical trials, SCH 530348 has now progressed to phase III development, where it is being evaluated in two large-scale trials involving almost 30,000 cardiac patients.
Structure
Thumb
SynonymsNot Available
External Identifiers
  • SCH 530348
  • TRA-SCH-530348
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIINot Available
CAS numberNot Available
WeightNot Available
Chemical FormulaNot Available
InChI KeyNot Available
InChINot Available
IUPAC NameNot Available
SMILESNot Available
Taxonomy
ClassificationNot classified
Pharmacology
IndicationInvestigated for use/treatment in cardiovascular disorders.
PharmacodynamicsNot Available
Mechanism of actionSCH-530348 is a thrombin receptor antagonist (TRA). It blocks the platelet PAR-1 receptor to which thrombin binds, thus inhibiting thrombin-induced activation of platelets.
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal AbsorptionNot AvailableNot Available
Blood Brain BarrierNot AvailableNot Available
Caco-2 permeableNot AvailableNot Available
P-glycoprotein substrateNot AvailableNot Available
P-glycoprotein inhibitor INot AvailableNot Available
P-glycoprotein inhibitor IINot AvailableNot Available
Renal organic cation transporterNot AvailableNot Available
CYP450 2C9 substrateNot AvailableNot Available
CYP450 2D6 substrateNot AvailableNot Available
CYP450 3A4 substrateNot AvailableNot Available
CYP450 1A2 substrateNot AvailableNot Available
CYP450 2C9 inhibitorNot AvailableNot Available
CYP450 2D6 inhibitorNot AvailableNot Available
CYP450 2C19 inhibitorNot AvailableNot Available
CYP450 3A4 inhibitorNot AvailableNot Available
CYP450 inhibitory promiscuityNot AvailableNot Available
Ames testNot AvailableNot Available
CarcinogenicityNot AvailableNot Available
BiodegradationNot AvailableNot Available
Rat acute toxicityNot AvailableNot applicable
hERG inhibition (predictor I)Not AvailableNot Available
hERG inhibition (predictor II)Not AvailableNot Available
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted PropertiesNot Available
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
AbciximabSCH-530348 may increase the anticoagulant activities of Abciximab.
AbciximabAbciximab may increase the antiplatelet activities of SCH-530348.
AcenocoumarolSCH-530348 may increase the anticoagulant activities of Acenocoumarol.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when SCH-530348 is combined with Acetylsalicylic acid.
Acetylsalicylic acidAcetylsalicylic acid may increase the antiplatelet activities of SCH-530348.
AlprostadilAlprostadil may increase the antiplatelet activities of SCH-530348.
AlteplaseSCH-530348 may increase the anticoagulant activities of Alteplase.
ALX-0081SCH-530348 may increase the anticoagulant activities of ALX-0081.
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when SCH-530348 is combined with Aminosalicylic Acid.
AnagrelideSCH-530348 may increase the anticoagulant activities of Anagrelide.
AnagrelideAnagrelide may increase the antiplatelet activities of SCH-530348.
AncrodSCH-530348 may increase the anticoagulant activities of Ancrod.
AnistreplaseSCH-530348 may increase the anticoagulant activities of Anistreplase.
Antithrombin III humanSCH-530348 may increase the anticoagulant activities of Antithrombin III human.
ApixabanSCH-530348 may increase the anticoagulant activities of Apixaban.
ArdeparinSCH-530348 may increase the anticoagulant activities of Ardeparin.
ArgatrobanSCH-530348 may increase the anticoagulant activities of Argatroban.
ArgatrobanArgatroban may increase the antiplatelet activities of SCH-530348.
AstaxanthinSCH-530348 may increase the anticoagulant activities of Astaxanthin.
AzelastineAzelastine may increase the antiplatelet activities of SCH-530348.
BatroxobinSCH-530348 may increase the anticoagulant activities of Batroxobin.
BecaplerminSCH-530348 may increase the anticoagulant activities of Becaplermin.
BemiparinSCH-530348 may increase the anticoagulant activities of Bemiparin.
BeraprostSCH-530348 may increase the anticoagulant activities of Beraprost.
BeraprostBeraprost may increase the antiplatelet activities of SCH-530348.
BivalirudinSCH-530348 may increase the anticoagulant activities of Bivalirudin.
CangrelorSCH-530348 may increase the anticoagulant activities of Cangrelor.
CangrelorCangrelor may increase the antiplatelet activities of SCH-530348.
CertoparinSCH-530348 may increase the anticoagulant activities of Certoparin.
CilostazolSCH-530348 may increase the anticoagulant activities of Cilostazol.
CilostazolCilostazol may increase the antiplatelet activities of SCH-530348.
Citric AcidSCH-530348 may increase the anticoagulant activities of Citric Acid.
ClopidogrelSCH-530348 may increase the anticoagulant activities of Clopidogrel.
ClopidogrelClopidogrel may increase the antiplatelet activities of SCH-530348.
CollagenaseThe risk or severity of adverse effects can be increased when SCH-530348 is combined with Collagenase.
Dabigatran etexilateSCH-530348 may increase the anticoagulant activities of Dabigatran etexilate.
DalteparinSCH-530348 may increase the anticoagulant activities of Dalteparin.
DanaparoidSCH-530348 may increase the anticoagulant activities of Danaparoid.
DasatinibDasatinib may increase the anticoagulant activities of SCH-530348.
DefibrotideSCH-530348 may increase the anticoagulant activities of Defibrotide.
DefibrotideDefibrotide may increase the antiplatelet activities of SCH-530348.
Deoxycholic AcidThe risk or severity of adverse effects can be increased when SCH-530348 is combined with Deoxycholic Acid.
DesirudinSCH-530348 may increase the anticoagulant activities of Desirudin.
DesmoteplaseSCH-530348 may increase the anticoagulant activities of Desmoteplase.
DextranSCH-530348 may increase the anticoagulant activities of Dextran.
Dextran 40SCH-530348 may increase the anticoagulant activities of Dextran 40.
Dextran 70SCH-530348 may increase the anticoagulant activities of Dextran 70.
Dextran 75SCH-530348 may increase the anticoagulant activities of Dextran 75.
DicoumarolSCH-530348 may increase the anticoagulant activities of Dicoumarol.
DiflunisalThe risk or severity of adverse effects can be increased when SCH-530348 is combined with Diflunisal.
DipyridamoleSCH-530348 may increase the anticoagulant activities of Dipyridamole.
DipyridamoleDipyridamole may increase the antiplatelet activities of SCH-530348.
DitazoleSCH-530348 may increase the anticoagulant activities of Ditazole.
Drotrecogin alfaSCH-530348 may increase the anticoagulant activities of Drotrecogin alfa.
Edetic AcidSCH-530348 may increase the anticoagulant activities of Edetic Acid.
EdoxabanSCH-530348 may increase the anticoagulant activities of Edoxaban.
EnoxaparinSCH-530348 may increase the anticoagulant activities of Enoxaparin.
EpinastineEpinastine may increase the antiplatelet activities of SCH-530348.
EpoprostenolSCH-530348 may increase the anticoagulant activities of Epoprostenol.
EpoprostenolEpoprostenol may increase the antiplatelet activities of SCH-530348.
EptifibatideSCH-530348 may increase the anticoagulant activities of Eptifibatide.
EptifibatideEptifibatide may increase the antiplatelet activities of SCH-530348.
Ethyl biscoumacetateSCH-530348 may increase the anticoagulant activities of Ethyl biscoumacetate.
FibrinolysinSCH-530348 may increase the anticoagulant activities of Fibrinolysin.
Fondaparinux sodiumSCH-530348 may increase the anticoagulant activities of Fondaparinux sodium.
GlucosamineGlucosamine may increase the antiplatelet activities of SCH-530348.
HeparinSCH-530348 may increase the anticoagulant activities of Heparin.
HirulogSCH-530348 may increase the anticoagulant activities of Hirulog.
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when SCH-530348 is combined with Ibritumomab tiuxetan.
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with SCH-530348.
IbudilastIbudilast may increase the antiplatelet activities of SCH-530348.
Icosapent ethylSCH-530348 may increase the antiplatelet activities of Icosapent ethyl.
IfenprodilSCH-530348 may increase the antiplatelet activities of Ifenprodil.
IloprostSCH-530348 may increase the anticoagulant activities of Iloprost.
IloprostIloprost may increase the antiplatelet activities of SCH-530348.
LepirudinSCH-530348 may increase the anticoagulant activities of Lepirudin.
LimaprostLimaprost may increase the antiplatelet activities of SCH-530348.
MesalazineThe risk or severity of adverse effects can be increased when SCH-530348 is combined with Mesalazine.
MilrinoneMilrinone may increase the antiplatelet activities of SCH-530348.
NadroparinSCH-530348 may increase the anticoagulant activities of Nadroparin.
NCX 4016SCH-530348 may increase the anticoagulant activities of NCX 4016.
NCX 4016NCX 4016 may increase the antiplatelet activities of SCH-530348.
NimesulideNimesulide may increase the antiplatelet activities of SCH-530348.
ObinutuzumabThe risk or severity of adverse effects can be increased when SCH-530348 is combined with Obinutuzumab.
Omega-3 fatty acidsOmega-3 fatty acids may increase the antiplatelet activities of SCH-530348.
OtamixabanSCH-530348 may increase the anticoagulant activities of Otamixaban.
ParnaparinSCH-530348 may increase the anticoagulant activities of Parnaparin.
Pentosan PolysulfateThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with SCH-530348.
Pentosan PolysulfateSCH-530348 may increase the anticoagulant activities of Pentosan Polysulfate.
PentoxifyllinePentoxifylline may increase the antiplatelet activities of SCH-530348.
PhenindioneSCH-530348 may increase the anticoagulant activities of Phenindione.
PhenprocoumonSCH-530348 may increase the anticoagulant activities of Phenprocoumon.
PlasminSCH-530348 may increase the anticoagulant activities of Plasmin.
PrasugrelSCH-530348 may increase the anticoagulant activities of Prasugrel.
PrasugrelPrasugrel may increase the antiplatelet activities of SCH-530348.
Protein CSCH-530348 may increase the anticoagulant activities of Protein C.
ProtocatechualdehydeSCH-530348 may increase the anticoagulant activities of Protocatechualdehyde.
ResveratrolResveratrol may increase the antiplatelet activities of SCH-530348.
ReteplaseSCH-530348 may increase the anticoagulant activities of Reteplase.
ReviparinSCH-530348 may increase the anticoagulant activities of Reviparin.
RidogrelRidogrel may increase the antiplatelet activities of SCH-530348.
RivaroxabanSCH-530348 may increase the anticoagulant activities of Rivaroxaban.
RosiglitazoneSCH-530348 may increase the anticoagulant activities of Rosiglitazone.
Salicylic acidThe risk or severity of adverse effects can be increased when SCH-530348 is combined with Salicylic acid.
SelexipagSCH-530348 may increase the anticoagulant activities of Selexipag.
SevofluraneSevoflurane may increase the antiplatelet activities of SCH-530348.
SRT501SRT501 may increase the antiplatelet activities of SCH-530348.
StreptokinaseSCH-530348 may increase the anticoagulant activities of Streptokinase.
SulodexideSCH-530348 may increase the anticoagulant activities of Sulodexide.
TenecteplaseSCH-530348 may increase the anticoagulant activities of Tenecteplase.
TesmilifeneTesmilifene may increase the antiplatelet activities of SCH-530348.
TicagrelorSCH-530348 may increase the anticoagulant activities of Ticagrelor.
TiclopidineSCH-530348 may increase the anticoagulant activities of Ticlopidine.
TiclopidineTiclopidine may increase the antiplatelet activities of SCH-530348.
TinzaparinSCH-530348 may increase the anticoagulant activities of Tinzaparin.
TipranavirTipranavir may increase the antiplatelet activities of SCH-530348.
TirofibanSCH-530348 may increase the anticoagulant activities of Tirofiban.
TirofibanTirofiban may increase the antiplatelet activities of SCH-530348.
TositumomabThe risk or severity of adverse effects can be increased when SCH-530348 is combined with Tositumomab.
TranilastSCH-530348 may increase the antiplatelet activities of Tranilast.
TrapidilSCH-530348 may increase the antiplatelet activities of Trapidil.
TreprostinilSCH-530348 may increase the anticoagulant activities of Treprostinil.
TreprostinilTreprostinil may increase the antiplatelet activities of SCH-530348.
TriflusalSCH-530348 may increase the anticoagulant activities of Triflusal.
TriflusalTriflusal may increase the antiplatelet activities of SCH-530348.
UrokinaseSCH-530348 may increase the anticoagulant activities of Urokinase.
Vitamin EVitamin E may increase the antiplatelet activities of SCH-530348.
VorapaxarSCH-530348 may increase the anticoagulant activities of Vorapaxar.
VorapaxarVorapaxar may increase the antiplatelet activities of SCH-530348.
WarfarinSCH-530348 may increase the anticoagulant activities of Warfarin.
XimelagatranSCH-530348 may increase the anticoagulant activities of Ximelagatran.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Thrombin receptor activity
Specific Function:
High affinity receptor for activated thrombin coupled to G proteins that stimulate phosphoinositide hydrolysis. May play a role in platelets activation and in vascular development.
Gene Name:
F2R
Uniprot ID:
P25116
Molecular Weight:
47439.83 Da
Comments
comments powered by Disqus
Drug created on November 18, 2007 11:27 / Updated on August 17, 2016 12:24